Almac Group Appoints Dr Stefan Mix as Head of Biocatalysis

Almac Group Appoints Dr Stefan Mix as Head of Biocatalysis

January 29, 2018

Craigavon, N.I., 29 January 2018 – Almac Group, the global contract development and manufacturing organization, has announced the appointment of Dr Stefan Mix to the position of Head of Biocatalysis, effective from 2 January 2018.

Stefan joined the Almac Sciences business in April 2005 as a chemist working in the lab on process development projects for chiral materials and has been part of the biocatalysis team since its beginnings. He has gained broad industrial experience including applications of biocatalysis, crystallization development, process development for chiral building blocks and APIs, and technology transfer to manufacturing network partners, and was promoted to Biocatalysis Team Leader in 2012.  All this time he has played a significant role in the development of Almac Sciences’ Biocatalysis Technology platform which has seen rapid growth and has multiple applications across a range of project scales and industry sectors.

In his new role, Stefan, who is the author of several publications will be responsible for the development and application of platform technologies within Almac Sciences leading a team of almost 50 scientists, in addition to supporting and directing commercialization of new technology.

Stefan will report directly to Professor Tom Moody, VP Technology Development & Commercialization, who congratulated him on his promotion: “Stefan’s wealth of knowledge, expertise and experience within biocatalysis and chemical synthesis has been critical to the success of our biocatalysis offering within Almac Sciences. I am delighted to announce Stefan’s promotion and wish him every success in his new role.”

Stefan was born in Berlin / East Germany, where he also completed his secondary education. After graduating with a Diploma in chemistry, he received his doctorate in 2004 from the Technical University of Berlin where he worked in a group under Professor Siegfried Blechert on stereoselective synthetic methodology and olefin metathesis.

###

About Almac Group

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organization that has organically grown over almost 50 years and now employs close to 5,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit almacgroup.com

Share

Back to news